EBV gp350-Ferritin vaccine / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection (clinicaltrials.gov) - P1 | N=83 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Epstein-Barr Virus Infections • Infectious Disease

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection (clinicaltrials.gov) - P1 | N=750 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting

Enrollment open • Epstein-Barr Virus Infections • Infectious Disease

Phase 1 Study of the Safety of an Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection (clinicaltrials.gov) - P1 | N=750 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1 trial • Epstein-Barr Virus Infections • Infectious Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (clinicaltrials.gov) - P1/2 | N=25 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=1000 ➔ 25

Enrollment change • Epstein-Barr Virus Infections • Infectious Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (clinicaltrials.gov) - P1/2 | N=1000 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2026 ➔ Apr 2027 | Trial primary completion date: Mar 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (clinicaltrials.gov) - P1/2 | N=1000 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (clinicaltrials.gov) - P1/2 | N=1000 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Mar 2024 ➔ Mar 2025

Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (clinicaltrials.gov) - P1/2 | N=1000 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting

Enrollment open • Epstein-Barr Virus Infections • Infectious Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (clinicaltrials.gov) - P1/2 | N=1000 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1/2 trial • Epstein-Barr Virus Infections • Infectious Disease